LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships

By Yahoo! Finance | Oct 28, 2024 at 01:58 PM EST

Corxel Pharmaceuticals and LENZ Therapeutics released positive Phase 3 trial data for LNZ100 in treating presbyopia in China. The study showed significant improvement in vision, boosting confidence in the product's potential approval and market performance.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.